Research Progress of New Generation EGFR-TKIs after Third-generation.
10.3779/j.issn.1009-3419.2020.102.28
- Author:
Yuanyuan LIU
1
;
Yihui LI
1
;
Jiangong WANG
1
Author Information
1. First Department of Comprehensive Treatment of Tumors, Tangshan People's Hospital,
North China University of Science and Technology, Tangshan 063000, China.
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor-tyrosine kinase inhibitors;
Lung neoplasms;
New generation
- From:
Chinese Journal of Lung Cancer
2020;23(11):970-975
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer has the highest mortality rate in the world. The first- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival time and quality of life of patients with non-small cell lung cancer (NSCLC) to some extent. However, after a period of progression-free survival, most patients develop drug resistance, in which T790M mutation is the mainly resistance mechanism. The third-generation EGFR-TKIs, represented by osimertinib, are found to have significant effect on this resistance. The effect is remarkable, but drug resistance is still inevitable. For example, C797S mutation, mesenchymal-epithelial transition (MET), RAS mutation, BRAF mutation, transformation of small cell lung cancer (SCLC), transformation of epithelial mesenchymal transition (EMT), etc. But, there is no standard and effective treatment after the third-generation EGFR-TKIs resistance. In this view, we summarize the research progress in the new generation EGFR-TKIs after third-generation, in order to provide some reference for the follow-up research and treatment.
.
